Study guide
9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy
ABIM Internal Medicine Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy
0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan
2 Chapter 1: Cardiovascular Disease (14% of Exam)
1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection
3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)
2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia
4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)
3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV
5 Chapter 4: Infectious Disease (9% of Exam)
4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections
6 Chapter 5: Pulmonary Disease (9% of Exam)
5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule
7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)
6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease
8 Chapter 7: Hematology (6% of Exam)
7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation
9 Chapter 8: Medical Oncology (6% of Exam)
8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care
10 Chapter 9: Nephrology & Urology (6% of Exam)
9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria
11 Chapter 10: Neurology (4% of Exam)
10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders
12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)
11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health
13 Chapter 12: Dermatology (3% of Exam)
12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease
14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)
13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications
15 Chapter 14: Geriatric Syndromes (3% of Exam)
14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings
16 Chapter 15: Allergy & Immunology (2% of Exam)
15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders
17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology
16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design
18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)
17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity
19 Chapter 18: Perioperative Medicine & Medical Consultation
18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications
20 Chapter 19: Ophthalmology (1% of Exam)
19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease
21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)
20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders
9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy
Key Takeaways Explain This Topic AI
Hypotension-induced injury, toxic injury, rhabdomyolysis, hepatorenal syndrome, disseminated atheroembolism and myeloma-induced kidney disease are enumerated under acute kidney injury.
Muddy brown granular casts indicate acute tubular necrosis, while bland sediment with concentrated urine suggests prerenal physiology.
Fractional excretion of sodium is uninterpretable after diuretic administration, where the fractional excretion of urea is used instead.
White cell casts with eosinophiluria and a temporally related drug exposure suggest acute interstitial nephritis, for which drug withdrawal is the primary treatment.
Cholesterol embolization after vascular instrumentation causes livedo reticularis, blue toes, eosinophilia and low complement with a subacute rise in creatinine.
Last updated: August 2026
Acute kidney injury (AKI) and glomerular disorders represent core competencies on the ABIM Internal Medicine certification exam. Mastery of acute azotemia requires distinguishing hemodynamic prerenal states from intrinsic parenchymal injury (such as acute tubular necrosis and acute interstitial nephritis), interpreting urinary indices and sediment microscopy, differentiating nephrotic from nephritic syndromes, and recognizing life-threatening complications that demand emergent renal replacement therapy.
1. KDIGO Staging & Classification of Acute Kidney Injury
The Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria define AKI by acute changes in serum creatinine (SCr) or oliguria. Staging stratifies disease severity, predicts in-hospital mortality, and guides the timing of nephrology consultation and renal replacement therapy.
KDIGO Staging Criteria
Stage Serum Creatinine (SCr) Criteria Urine Output (UOP) Criteria
Stage 1 SCr 1.5–1.9 times baseline OR >=0.3 mg/dL (>=26.5 µmol/L) increase within 48 hours <0.5 mL/kg/h for 6 to 12 hours
Stage 2 SCr 2.0–2.9 times baseline <0.5 mL/kg/h for >=12 hours
Stage 3 SCr >=3.0 times baseline OR SCr >=4.0 mg/dL (>=353.6 µmol/L) with acute rise >=0.5 mg/dL OR Initiation of Renal Replacement Therapy (RRT) OR in patients <18y, decrease in eGFR to <35 mL/min/1.73m2 <0.3 mL/kg/h for >=24 hours OR Anuria for >=12 hours
Clinical Pearl — Baseline Creatinine Identification: When baseline serum creatinine is unknown, use the lowest stable value documented within the preceding 3 to 12 months. In oliguric patients who receive aggressive IV fluid resuscitation, dilutional decrease in serum creatinine can mask the true severity of AKI; always account for positive fluid balance.
2. Diagnostic Evaluation: Prerenal Azotemia vs. Acute Tubular Necrosis (ATN)
Determining whether an acute decline in GFR is due to renal hypoperfusion ( prerenal azotemia ) or ischemic/nephrotoxic tubular cell death ( acute tubular necrosis ) is the primary diagnostic challenge in hospitalized patients.
Diagnostic Urinary Indices
Fractional Excretion of Sodium (FeNa): FeNa = Urine Na × Serum Cr Serum Na × Urine Cr × 100 \text{FeNa} = \frac{\text{Urine Na} \times \text{Serum Cr}}{\text{Serum Na} \times \text{Urine Cr}} \times 100 FeNa = Serum Na × Urine Cr Urine Na × Serum Cr × 100
FeNa < 1%: Suggests intact tubular reabsorption of sodium in response to decreased renal perfusion ( prerenal azotemia ).
FeNa > 2%: Suggests tubular epithelial cell injury with loss of sodium-reabsorbing capacity ( ATN ).
FeNa Limitations & Exceptions: FeNa can be <1% in ATN caused by iodinated radiocontrast nephropathy, rhabdomyolysis/myoglobinuria, acute glomerulonephritis, and severe sepsis with renal vasoconstriction. FeNa can be >1% in prerenal azotemia if the patient has received diuretic therapy within the preceding 24–48 hours or has pre-existing CKD with salt-wasting.
Fractional Excretion of Urea (FeUrea): FeUrea = Urine Urea Nitrogen × Serum Cr Serum BUN × Urine Cr × 100 \text{FeUrea} = \frac{\text{Urine Urea Nitrogen} \times \text{Serum Cr}}{\text{Serum BUN} \times \text{Urine Cr}} \times 100 FeUrea = Serum BUN × Urine Cr Urine Urea Nitrogen × Serum Cr × 100
Primary Indication: Essential when a patient is receiving loop diuretics (e.g., Furosemide, Bumetanide), because loop diuretics block Na+/K+/2Cl- cotransporters in the thick ascending limb, artificially elevating urine sodium and FeNa.
FeUrea < 35%: Strongly indicates prerenal azotemia (urea reabsorption in the proximal tubule is passive and enhanced by hypovolemia, independent of loop diuretic actions in the loop of Henle).
FeUrea > 50%: Indicates ATN .
Comparative Diagnostic Matrix
Diagnostic Parameter Prerenal Azotemia Acute Tubular Necrosis (ATN) Acute Interstitial Nephritis (AIN) Acute Glomerulonephritis (GN)
- BUN : Serum Cr Ratio >20 : 1 (avid urea reabsorption) 10–15 : 1 10–15 : 1 >20 : 1 (in severe oliguria)
- Urine Sodium (UNa) <20 mEq/L >40 mEq/L Variable (>20–40 mEq/L) <20 mEq/L
- Urine Osmolality >500 mOsm/kg (concentrated) <350 mOsm/kg (isosthenuric) <350–400 mOsm/kg >500 mOsm/kg
- FeNa <1% >2% Variable (>1%) <1%
- FeUrea (on diuretics) <35% >50% >50% <35%
Urine Sediment Microscopy Normal, hyaline casts Muddy brown granular casts , renal tubular epithelial (RTE) cells WBC casts , WBCs, eosinophiluria Dysmorphic RBCs (acanthocytes) , RBC casts , sub-nephrotic proteinuria
3. Urine Microscopy & Cast Typology
Microscopic examination of fresh, uncentrifuged or gently centrifuged urine sediment is the most cost-effective diagnostic tool in nephrology.
Muddy Brown Granular Casts / RTE Cell Casts: Pathognomonic for Acute Tubular Necrosis (ATN) . Formed by sloughed necrotic tubular epithelial cells that degenerate into coarse, dark granular debris embedded within Tamm-Horsfall mucoprotein.
WBC Casts & Eosinophiluria: Hallmark of Acute Interstitial Nephritis (AIN) . WBC casts confirm renal parenchymal inflammation (differentiating AIN or pyelonephritis from lower urinary tract cystitis). Eosinophiluria is visualized with Hansel or Wright stain (>1% eosinophils); however, its sensitivity and specificity are poor (frequently absent in biopsy-proven AIN).
Dysmorphic RBCs & RBC Casts: Diagnostic of Glomerulonephritis (GN) or vasculitis. Glomerular red blood cells undergo mechanical and osmotic shear stress across a disrupted glomerular basement membrane, producing acanthocytes (ring-shaped RBCs with vesicle-like blebs / "Mickey Mouse ears").
Broad Waxy Casts: Indicative of Advanced Chronic Kidney Disease (CKD) with dilated, atrophic, sclerotic tubules with low flow.
Hyaline Casts: Composed purely of Tamm-Horsfall mucoprotein; seen in concentrated urine, prerenal azotemia, strenuous exercise, or normal states.
Fatty Casts & Oval Fat Bodies ("Maltese Cross"): Highly characteristic of Nephrotic Syndrome . Tubular cells engorged with reabsorbed filtered cholesterol and lipoproteins produce polarized light birefringence.
Crystals:
Envelope / Dumbbell: Calcium oxalate (ethylene glycol poisoning, hyperoxaluria).
Needle / Rhomboid: Uric acid (acute urate nephropathy in tumor lysis syndrome).
Coffin-lid: Triple phosphate / struvite (Proteus, Klebsiella urosepsis).
Hexagonal: Cystinuria.
Loading diagram... Diagnostic Algorithm for Acute Kidney Injury & Glomerular Disease Stratification
4. Acute Interstitial Nephritis (AIN)
Acute interstitial nephritis is an immune-mediated tubulointerstitial inflammation causing acute renal dysfunction.
Etiologies
Medications (>75% of cases):
Antibiotics: Penicillins (methicillin, ampicillin), cephalosporins, fluoroquinolones (ciprofloxacin), sulfonamides, rifampin, vancomycin.
Proton Pump Inhibitors (PPIs): Omeprazole, pantoprazole, esomeprazole (frequently insidious onset weeks to months after starting therapy without overt systemic allergic features).
NSAIDs & COX-2 Inhibitors: Often presents uniquely as AIN combined with nephrotic-range proteinuria (due to concurrent minimal change-like podocyte effacement).
Immune Checkpoint Inhibitors (ICIs): Pembrolizumab, nivolumab, ipilimumab (delayed onset after multiple cycles, mediated by T-cell reactivation).
Infections (5–10%): Legionella, Leptospira, CMV, EBV, HIV, Streptococcus.
Autoimmune / Systemic Diseases (10–15%): Sarcoidosis, Sjögren syndrome, Systemic Lupus Erythematosus, Tubulointerstitial Nephritis and Uveitis (TINU syndrome).
Clinical Presentation & Workup
The Classic Triad: Low-grade fever, maculopapular morbilliform rash, and peripheral eosinophilia is present in <30% of patients . Do not exclude AIN based on the absence of this triad!
Laboratory Findings: Progressive rise in serum creatinine, sterile pyuria, WBC casts, mild non-nephrotic proteinuria (<1–2 g/day; except NSAID-induced), and elevated serum IgE.
Definitive Diagnosis: Percutaneous Renal Biopsy is the gold standard, demonstrating diffuse interstitial edema, dense inflammatory infiltration (T-lymphocytes, monocytes, plasma cells, and eosinophils), and tubulitis.
Management Strategy:
Immediate Cessation of Offending Agent: The single most important therapeutic maneuver.
Systemic Corticosteroids: Indicated if serum creatinine fails to improve within 3 to 5 days of drug withdrawal, or if severe renal failure/biopsy-confirmed extensive interstitial inflammation is present. Regimen: Oral Prednisone 1 mg/kg/day (maximum 60–80 mg/day) for 2 to 4 weeks , followed by a gradual taper over 4 to 6 weeks. Early initiation within 7–14 days of onset prevents irreversible chronic interstitial fibrosis.